Video Experimental Relacionado
Updated: Sep 10, 2025
07:41
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
2.0K
Uso de Vericiguat en el manejo de la insuficiencia cardíaca derecha después de la implantación del dispositivo de
Tasuku Hada1, Takuya Watanabe1, Satsuki Fukushima2
1From the Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
ASAIO journal (American Society for Artificial Internal Organs : 1992)
|August 22, 2025
Resumen
Vericiguat, un estimulador soluble de guanilato ciclasa, mejoró la insuficiencia cardíaca derecha (IRD) en un paciente con un dispositivo de asistencia ventricular izquierda (LVAD). Este hallazgo sugiere al vericiguat como un tratamiento potencial para la implantación de RHF post-LVAD.
Área de la Ciencia:
- Cardiología
- Farmacología
Sus antecedentes:
- La insuficiencia cardíaca derecha es una causa significativa de mortalidad en pacientes con dispositivos de asistencia ventricular izquierda (LVAD).
- Las estrategias de tratamiento actuales para la RHF post-LVAD son limitadas.
- Vericiguat, un estimulador soluble de la guanylata ciclasa, es prometedor para el tratamiento de la insuficiencia cardíaca.
Objetivo del estudio:
- Evaluar la eficacia de vericiguat en el tratamiento de la insuficiencia cardíaca derecha refractaria (IFR) en un paciente con un dispositivo de asistencia ventricular izquierda (LVAD).
Principales métodos:
- Informe de caso de una paciente de 62 años con insuficiencia cardíaca avanzada y implantación de LVAD.
- Cateterismo del corazón derecho para evaluar la hipertensión pulmonar.
- Administración de vericiguat después del fracaso de las terapias convencionales (inotrópicos, vasodilatadores pulmonares) para la RHF postoperatoria.
Principales resultados:
- La administración de vericiguat condujo a un aumento del gasto cardíaco y a una mejora de los síntomas de la RHF.
- Se observó una optimización de la posición del tabique interventricular.
- La condición del paciente mejoró después de la adición de vericiguat.
Conclusiones:
- Vericiguat puede representar una nueva opción terapéutica para el tratamiento de la insuficiencia cardíaca derecha en pacientes con LVAD.
- Se requiere más investigación para confirmar el papel de vericiguat en esta población de pacientes.
Videos de Conceptos Relacionados
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:29Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
01:25Mitral Regurgitation III: Medical Management
30
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:25Aortic Regurgitation III: Medical Management
42
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
42